Agios Pharmaceuticals, Inc.
As of Oct 22, 2026, Agios Pharmaceuticals is in Stage 3, the topping phase, now in week 6 (since Sep 16, 2026). It closed at $37.19, 18.2% below its 52-week high and above its 200-day average, which is rising.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is AGIO early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
AGIO among Biotechnology229th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …229 | AGIO | Stage 3 · wk 6 | 43 | +8.8% |
Agios Pharmaceuticals: quick answers
What stage is Agios Pharmaceuticals in?
As of Oct 22, 2026, Agios Pharmaceuticals (AGIO) is in Stage 3, the topping phase. It entered Stage 3 on Sep 16, 2026 and is in week 6. What the four stages mean
Is Agios Pharmaceuticals in an uptrend?
Its uptrend has stalled. Agios Pharmaceuticals is in Stage 3, the topping phase that follows an advance. It trades 18.2% above its 200-day average, which is rising.
How far is Agios Pharmaceuticals from its 52-week high?
Agios Pharmaceuticals closed at $37.19 on Oct 22, 2026, 18.2% below its 52-week high of $45.49. Its 52-week low is $22.34.
How has Agios Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Agios Pharmaceuticals is down 14.4% over the past year and up 36.8% so far in 2026.
Which sector and industry is Agios Pharmaceuticals in?
Agios Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.